Zobrazeno 1 - 10
of 829
pro vyhledávání: '"Fabien, Zoulim"'
Autor:
Alexia Paturel, Francesca Casuscelli di Tocco, Delphine Bousquet, Marie-Laure Plissonnier, Xavier Grand, Hyosun Tak, Françoise Berby, Caroline Scholtès, Barbara Testoni, Fabien Zoulim, Massimo Levrero
Publikováno v:
JHEP Reports, Vol 6, Iss 10, Pp 101124- (2024)
Background & Aims: Circulating HBV RNAs have been proposed as a biomarker that reflects the transcriptional activity of covalently closed circular DNA (cccDNA) and may help to evaluate HBV treatment activity. Different research assays have been propo
Externí odkaz:
https://doaj.org/article/df2fae496bcf4f019cadd2a168b5de9a
Autor:
Armando Andres Roca Suarez, Marie-Laure Plissonnier, Maud Michelet, Anaëlle Dubois, Sarah Heintz, Maria Saez-Palma, Marion Delphin, Isabelle Bordes, Jennifer Molle, Audrey Diederichs, Mélanie Rodà, Emmanuel Combe, Léa Mougené, Guillaume Giraud, Xavier Grand, Michel Rivoire, Massimo Levrero, Barbara Testoni, Fabien Zoulim
Publikováno v:
STAR Protocols, Vol 5, Iss 4, Pp 103359- (2024)
Summary: The liver microenvironment contains a wide variety of monocyte and macrophage populations. Here, we present a protocol for the specific isolation of liver-resident macrophages, known as Kupffer cells (KCs), from human liver resections. We de
Externí odkaz:
https://doaj.org/article/252542b9b4134b41be7a86861021ea81
Autor:
Selma El Messaoudi, Ségolène Brichler, Claire Fougerou-Leurent, Emmanuel Gordien, Athenaïs Gerber, Amal Kortebi, Garance Lagadic, Miroslava Subic-Levrero, Sophie Metivier, Stanislas Pol, Anne Minello, Vlad Ratziu, Vincent Leroy, Philippe Mathurin, Laurent Alric, Fatoumata Coulibaly, Jean-Michel Pawlotsky, Fabien Zoulim, Victor de Lédinghen, Jérémie Guedj
Publikováno v:
JHEP Reports, Vol 6, Iss 8, Pp 101070- (2024)
Background & Aims: Bulevirtide is a first-in-class entry inhibitor antiviral treatment for chronic hepatitis D. The viral kinetics during bulevirtide therapy and the effect of combining bulevirtide with pegylated-interferon (Peg-IFN) are unknown. Met
Externí odkaz:
https://doaj.org/article/73e8c7b7ac3f4fe3a3996b07dd278246
Autor:
Victor de Lédinghen, Claire Fougerou-Leurent, Estelle Le Pabic, Stanislas Pol, Dulce Alfaiate, Karine Lacombe, Marie-Noëlle Hilleret, Caroline Lascoux-Combe, Anne Minello, Eric Billaud, Isabelle Rosa, Anne Gervais, Vlad Ratziu, Nathalie Ganne, Georges-Philippe Pageaux, Vincent Leroy, Véronique Loustaud-Ratti, Philippe Mathurin, Julie Chas, Caroline Jezequel, Sophie Métivier, Jérôme Dumortier, Jean-Pierre Arpurt, Tarik Asselah, Bruno Roche, Antonia Le Gruyer, Marc-Antoine Valantin, Caroline Scholtès, Emmanuel Gordien, Christelle Tual, Amel Kortebi, Fatoumata Coulibaly, Eric Rosenthal, Miroslava Subic-Levrero, Dominique Roulot, Fabien Zoulim, François Raffi, Laurent Alric, Patrick Miailhes, Albert Tran, Christiane Stern, Xavier Causse, Simona Tripon, Ghassan Riachi, Olivier Chazouillères, Armando Abergel, Louis d’Alteroche, Jérôme Gournay, Garance Lagadic, Patrizia Carrieri, Ségolène Brichler, Martin Siguier, Jessica Krause, Juliette Foucher, Souad Ben Ali, Magdalena Meszaros, Anne Varaut, Valérie Canva
Publikováno v:
JHEP Reports, Vol 6, Iss 8, Pp 101057- (2024)
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfe
Externí odkaz:
https://doaj.org/article/9c555ee813a44c469f08eabb29b34b1d
Autor:
Hyunjae Shin, Won-Mook Choi, Seung Up Kim, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Fabien Zoulim
Publikováno v:
JHEP Reports, Vol 6, Iss 7, Pp 101089- (2024)
Background & Aims: The association between hepatitis B envelope antigen (HBeAg) seroclearance during long-term nucleos(t)ide analogue (NA) treatment and the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) remains unc
Externí odkaz:
https://doaj.org/article/fc34919f2cb14440bf605509859aac29
Publikováno v:
Viruses, Vol 16, Iss 10, p 1565 (2024)
Hepatitis B virus (HBV) infection remains a significant global health challenge, leading to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Covalently closed circular DNA (cccDNA) and integrated HBV DNA are pivotal in maintain
Externí odkaz:
https://doaj.org/article/aa9c586dfd99457e8f73ae4d2ad1b44f
Autor:
Elena M. Smekalova, Maria G. Martinez, Emmanuel Combe, Anuj Kumar, Selam Dejene, Dominique Leboeuf, Chao-Ying Chen, J. Robert Dorkin, Lan Shuan Shuang, Sarah Kieft, Lauren Young, Luis Alberto Barrera, Michael S. Packer, Giuseppe Ciaramella, Barbara Testoni, Francine Gregoire, Fabien Zoulim
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 1, Pp 102112- (2024)
Chronic hepatitis B virus (HBV) infection remains a global health problem due to the lack of treatments that prevent viral rebound from HBV covalently closed circular (ccc)DNA. In addition, HBV DNA integrates in the human genome, serving as a source
Externí odkaz:
https://doaj.org/article/079b4123912c4274a76ea24a7da66556
Publikováno v:
Viruses, Vol 16, Iss 4, p 615 (2024)
Chronic hepatitis B (CHB) virus infection is a major public health burden and the leading cause of hepatocellular carcinoma. Despite the efficacy of current treatments, hepatitis B virus (HBV) cannot be fully eradicated due to the persistence of its
Externí odkaz:
https://doaj.org/article/c55e945896b14e15936653f80f11ab8c
Publikováno v:
eGastroenterology, Vol 1, Iss 2 (2023)
In spite of the fact that safe and effective vaccines have been available for over 40 years, hepatitis B virus (HBV) remains a major public health problem, as there are 296 million chronically HBV-infected individuals worldwide and 820 000 HBV-relate
Externí odkaz:
https://doaj.org/article/cdf04f4ae4754474a938ed2336cf1df8
Autor:
Barbara Testoni, Armando Andres Roca Suarez, Arianna Battisti, Marie-Laure Plissonnier, Marintha Heil, Thierry Fontanges, François Villeret, Yasmina Chouik, Massimo Levrero, Upkar Gill, Patrick Kennedy, Fabien Zoulim
Publikováno v:
JHEP Reports, Vol 5, Iss 10, Pp 100841- (2023)
Background & Aims: Finite duration of treatment associated with HBsAg loss is the current goal for improved therapeutic approaches against chronic HBV infection, as it indicates elimination or durable inactivation of intrahepatic covalently closed ci
Externí odkaz:
https://doaj.org/article/0821224364c24111a53006fcc65a7417